Representing ~15% of these biologically and clinically distinct forms of breast cancer [4,5,6], basal-like carcinomas are of particular interest to clinicians and researchers due to their characteristically poor prognosis and resistance to existing molecularly-targeted treatment modalities, such as endocrine therapy (e.g., tamoxifen and aromatase inhibitors) for hormone receptor-positive disease or trastuzumab for human epidermal growth factor receptor-2 (HER2)-positive disease, leaving cytotoxic chemotherapy as the principal systemic treatment [7,8,9,10]. The gene discussed is ERBB2; the disease is carcinoma.